Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Larcher

Showing results (1-10 of 334) with videos related to

Pageof 34
Sort By:
The Journal of Urology|April 8, 2015
Re: Editorial Comment on Clinical Performance of Serum Isoform (-2)proPSA (p2PSA) and its Derivatives, Namely %p2PSA and PHI (Prostate Health Index) in Men Younger than 60 Years of Age: Results from a Multicentric European Study: S. S. Taneja J Urol 2014;192:421Nicola Fossati, Massimo Lazzeri, Alessandro Larcher
Annals of Translational Medicine|February 5, 2020
Acute kidney injury after partial nephrectomy: transient or permanent kidney damage?-Impact on long-term renal functionGiuseppe Rosiello, Umberto Capitanio, Alessandro Larcher
European Urology Focus|October 1, 2019
Re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2019.06.002Francesco Montorsi, Alessandro Larcher, Umberto Capitanio
European Urology|November 7, 2021
Re: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 2021;385:683-94: Adjuvant Pembrolizumab After Nephrectomy: A Plea to Reconsider the Need for Lymph Node DissectionUmberto Capitanio, Alessandro Larcher, Francesco Montorsi
The Journal of Urology|February 26, 2021
Editorial CommentGiuseppe Fallara, Alessandro Larcher, Umberto Capitanio
BJU International|January 19, 2019
Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomyUmberto Capitanio, Alessandro Larcher, Francesco Montorsi
European Urology|July 23, 2019
Surgical Safety of Cytoreductive Nephrectomy Following Systemic Therapy: What Should We Look For?Umberto Capitanio, Francesco Montorsi, Alessandro Larcher
European Urology Focus|October 20, 2018
The Past, the Present, and the Future of Robotic Urology: Robot-assisted Surgery and Human-assisted RobotsAlexandre Mottrie, Alessandro Larcher, Vipul Patel
Urology|March 16, 2016
Author ReplyVincent Trudeau, Pierre I Karakiewicz, Alessandro Larcher
International Journal of Nephrology and Renovascular Disease|November 8, 2014
Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidenceMaxine Sun, Alessandro Larcher, Pierre I Karakiewicz
Pageof 34

Showing results (1-10 of 334) with videos related to

Sort By:
Pageof 34
The Journal of Urology|April 8, 2015
Re: Editorial Comment on Clinical Performance of Serum Isoform (-2)proPSA (p2PSA) and its Derivatives, Namely %p2PSA and PHI (Prostate Health Index) in Men Younger than 60 Years of Age: Results from a Multicentric European Study: S. S. Taneja J Urol 2014;192:421Nicola Fossati, Massimo Lazzeri, Alessandro Larcher
Annals of Translational Medicine|February 5, 2020
Acute kidney injury after partial nephrectomy: transient or permanent kidney damage?-Impact on long-term renal functionGiuseppe Rosiello, Umberto Capitanio, Alessandro Larcher
European Urology Focus|October 1, 2019
Re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2019.06.002Francesco Montorsi, Alessandro Larcher, Umberto Capitanio
European Urology|November 7, 2021
Re: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 2021;385:683-94: Adjuvant Pembrolizumab After Nephrectomy: A Plea to Reconsider the Need for Lymph Node DissectionUmberto Capitanio, Alessandro Larcher, Francesco Montorsi
The Journal of Urology|February 26, 2021
Editorial CommentGiuseppe Fallara, Alessandro Larcher, Umberto Capitanio
BJU International|January 19, 2019
Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomyUmberto Capitanio, Alessandro Larcher, Francesco Montorsi
European Urology|July 23, 2019
Surgical Safety of Cytoreductive Nephrectomy Following Systemic Therapy: What Should We Look For?Umberto Capitanio, Francesco Montorsi, Alessandro Larcher
European Urology Focus|October 20, 2018
The Past, the Present, and the Future of Robotic Urology: Robot-assisted Surgery and Human-assisted RobotsAlexandre Mottrie, Alessandro Larcher, Vipul Patel
Urology|March 16, 2016
Author ReplyVincent Trudeau, Pierre I Karakiewicz, Alessandro Larcher
International Journal of Nephrology and Renovascular Disease|November 8, 2014
Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidenceMaxine Sun, Alessandro Larcher, Pierre I Karakiewicz
Pageof 34